11 |
Identification et caractérisation des cibles transcriptionnelles de ETV6, un facteur de transcription impliqué dans la leucémie de l’enfant.Malouf, Camille 02 1900 (has links)
La leucémie lymphoblastique aiguë (LLA) est responsable d’environ 25% de l’ensemble des cancers pédiatriques. Chez 85% des enfants diagnostiqués, la LLA entraîne une prolifération massive et incontrôlée de lymphocytes immatures de type précurseurs B dans la moelle osseuse (LLA pré-B). Des avancées intéressantes ont été faites au cours des trente dernières années et ont mené à une augmentation de l’efficacité des traitements thérapeutiques. Plus de 80% des enfants atteints de LLA seront guéris de cette maladie. Malheureusement, ces traitements manquent de spécificité à cause du manque de connaissances sur les mécanismes moléculaires impliqués durant l’initiation et le développement de la LLA pré-B pédiatrique. En d’autres termes, nous connaissons peu de chose sur l’étiologie de cette maladie. Plus de 25% des enfants atteints de la LLA pré-B présentent la translocation chromosomique t(12;21)(p13;q22) qui implique les gènes ETV6 et AML1. Celle-ci est formée in utero et mène à l’expression de la protéine chimère transcriptionnelle ETV6-AML1, dont la présence seule ne suffit pas au développement de la LLA pré-B. Ainsi, d’autres événements génétiques sont nécessaires au développement de cette leucémie. La délétion de l’allèle résiduel de ETV6 est un événement génétique fréquemment rencontré au moment du diagnostic de la LLA pré-B t(12;21)+. Cette délétion entraîne l’inactivation complète de ETV6 dans les lymphocytes pré-B leucémiques. ETV6 est un répresseur transcriptionnel de la famille Ets. Mon hypothèse de recherche est que ETV6 agit comme gène suppresseur de tumeur dans la LLA pré-B pédiatrique. L’inactivation de ETV6 causerait une dérégulation de l’expression de ses cibles transcriptionnelles et, par le fait même, favoriserait l’initiation et le déroulement de la leucémogenèse pédiatrique. Dans le cadre de mon projet, comme peu de cibles transcriptionnelles de ETV6 sont connues, j’ai effectué des expériences d’immunoprécipitation de la chromatine et des essais luciférases qui ont permis d’identifier six nouvelles cibles transcriptionnelles: TP53 (p53 et Δ133p53), SPHK1, IL-18, PTGER4 et LUM. J’ai démontré que la régulation transcriptionnelle médiée par ETV6 requiert la présence de ses deux domaines fonctionnels: PNT (interactions protéiques) et ETS (liaison à l’ADN). Ces domaines favorisent la reconnaissance d’un site EBS consensus dans une région située près du promoteur de base. Ce mécanisme peut dépendre du promoteur régulé par ETV6, mais également du contexte cellulaire. Des études fonctionnelles réalisées sur des lymphocytes pré-B leucémiques ont permis de mesurer l’impact de la dérégulation de l’expression des cibles transcriptionnelles de ETV6 sur trois voies biologiques: la prolifération cellulaire, l’apoptose induite par un stress génotoxique et la migration cellulaire dirigée par la voie de signalisation CXCL12/CXCR4. Ceci a permis de démontrer l’implication des gènes SPHK1, IL-18 et PTGER4 durant la leucémogenèse pédiatrique.
Cette étude est une des premières à suggérer le rôle de ETV6 comme gène suppresseur de tumeur dans la LLA pré-B pédiatrique. Suite à l’inactivation du répresseur transcriptionnel ETV6, l’augmentation de l’expression de ses cibles transcriptionnelles favoriserait la prolifération et la survie des lymphocytes pré-B leucémiques dans la moelle osseuse. L’identification de nouveaux gènes impliqués dans le développement de la LLA pré-B pédiatrique ouvre la porte au
développement de nouveaux traitements thérapeutiques qui pourront présenter une meilleure spécificité envers l’étiologie de la maladie. / Acute lymphoblastic leukemia (ALL) accounts for approximately 25% of all paediatric cancers. Approximately 85% of ALL cases happen in immature B precursors lymphocytes (pre-B ALL). Pre-B ALL is a sporadic cancer that leads to the massive proliferation of leukemia pre-B lymphocytes in the bone marrow. During the past 30 years, the scientific community has developed efficient therapeutic treatments against paediatric ALL, reaching more than 80% cure rate. However, these treatments lack specificity because of the lack of knowledge regarding the molecular mechanisms involved in the initiation and progression of paediatric pre-B ALL. In other words, we know little about the aetiology of this disease.
Approximately 25% of children affected with pre-B ALL carry the chromosomal translocation t(12;21)(p13;q22) involving the ETV6 and AML1 genes. This translocation originates in utero and leads to the expression of the transcriptional chimera ETV6-AML1, which alone is insufficient to trigger the development of pre-B ALL. Therefore, other genetic events would be required to initiate paediatric leukemogenesis. The deletion of the residual allele of ETV6 is frequently observed at the diagnosis of pre-B ALL t(12;21)+. This leads to the complete inactivation of ETV6 in leukemia pre-B lymphocytes. ETV6 is a transcriptional repressor of the Ets family. My research hypothesis is that ETV6 acts as a tumour suppressor gene in paediatric pre-B ALL. The inactivation of ETV6 would lead to the deregulated expression of its transcriptional targets and, consequently, would favour the initiation and progression of paediatric leukemogenesis. Given the fact that only very few ETV6 transcriptional targets are known, I initially performed chromatin immunoprecipitation experiments and luciferase assays that enabled the identification of six novel transcriptional targets: TP53 (p53 and Δ133p53), SPHK1, IL-18, PTGER4 and LUM. The ETV6-mediated transcriptional regulation involves both functional domains: PNT (protein interactions) and ETS (DNA-binding domain). These functional domains facilitate the recognition of consensus EBS sites located in a region close to the basal promoter, a molecular mechanism used according to the target promoter and cellular context. Functional studies using leukemia pre-B lymphocytes were useful to understand the role of the ETV6 transcriptional targets during cell proliferation, induction of apoptosis and cell migration through the CXC12/CXCR4 signalling pathway. These functional studies showed the implication of SPHK1, IL-18 and PTGER4 genes during paediatric leukemogenesis.
This study is one of the first to support the role of ETV6 as a tumour suppressor gene in paediatric pre-B ALL. Once ETV6 is inactivated, the increased expression of its transcriptional targets favours the proliferation and survival of leukemia pre-B lymphocytes in the bone marrow. The identification of new genes involved in the development of paediatric pre-B ALL opens new doors to the development of therapeutic treatments with a better specificity toward the aetiology of the disease.
|
12 |
Identification et caractérisation des cibles transcriptionnelles de ETV6, un facteur de transcription impliqué dans la leucémie de l’enfantMalouf, Camille 02 1900 (has links)
No description available.
|
13 |
Role fúzního proteinu ETV6-RUNX1 v citlivosti leukemických buněk na L-asparaginázu / The role of ETV6-RUNX1 fusion protein in the sensitivity of leukemic cells to L-asparaginaseStaněk, Petr January 2018 (has links)
Translocation t(12;21) with the presence of the fusion gene ETV6-RUNX1 (TEL-AML1) is the most common chromosomal aberration found in acute lymphoblastic leukemia in childhood. The occurrence of the ETV6-RUNX1 is associated with excellent prognosis and high sensitivity to the treatment with the enzyme L-asparaginase (ASNase). Resistance to the drug aggravates the outlook of the patient and increases the risk of treatment failure, therefore, the CLIP working group has been for a long time involved in the identification of the mechanism of action of ASNase and the origin of the resistance to it. This thesis follows previous findings of the group and is devoted to the analysis of the importance of ETV6-RUNX1 and signalization and metabolic changes accompanying shifts in the L-asparaginase resistance. In the first part of the thesis, the knockout clones with stable increased resistance to ASNase have been established thanks to the CRISPR/Cas9 system, which created frameshift in the fusion gene. The accomplishment in this regard and removal of the fusion protein was confirmed on the level of DNA, mRNA a protein expression. The presence of other significant chromosomal aberrations affection the sensitivity to ASNase was ruled out by the means of SNP analysis. In the second part of the project, the signalization...
|
14 |
Role fúzního proteinu ETV6-RUNX1 v citlivosti leukemických buněk na L-asparaginázu / The role of ETV6-RUNX1 fusion protein in the sensitivity of leukemic cells to L-asparaginaseStaněk, Petr January 2018 (has links)
Translocation t(12;21) with the presence of the fusion gene ETV6-RUNX1 (TEL-AML1) is the most common chromosomal aberration found in acute lymphoblastic leukemia in childhood. The occurrence of the ETV6-RUNX1 is associated with excellent prognosis and high sensitivity to the treatment with the enzyme L-asparaginase (ASNase). Resistance to the drug aggravates the outlook of the patient and increases the risk of treatment failure, therefore, the CLIP working group has been for a long time involved in the identification of the mechanism of action of ASNase and the origin of the resistance to it. This thesis follows previous findings of the group and is devoted to the analysis of the importance of ETV6-RUNX1 and signalization and metabolic changes accompanying shifts in the L-asparaginase resistance. In the first part of the thesis, the knockout clones with stable increased resistance to ASNase have been established thanks to the CRISPR/Cas9 system, which created frameshift in the fusion gene. The accomplishment in this regard and removal of the fusion protein was confirmed on the level of DNA, mRNA a protein expression. The presence of other significant chromosomal aberrations affection the sensitivity to ASNase was ruled out by the means of SNP analysis. In the second part of the project, the signalization...
|
15 |
Identification de transcrits modulés par ETV6 : un gène candidat suppresseur de tumeurBoily, Gino January 2005 (has links)
Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.
|
16 |
Korelace molekulárně-genetických a morfologických znaků vzácných nádorů slinných žláz / Correlation of Molecular-Genetic and Morphological Markers of Rare Salivary Gland TumorsŠteiner, Petr January 2018 (has links)
Thesis deals with relationship between histomorphological and molecular-genetic findings of selected salivary gland tumors. Author, as a molecular-cytogeneticist mainly focused on detection of tumor-specific translocations of the salivary gland tumors which can serve as differential diagnostic markers. The thesis is composed as a commented files of authors own publications, and it is divided into four parts. First part deepens the knowledge of salivary adenoid cystic carcinoma. It was proved, that t(6;9)(q22-23;p23-24) resulting in fusion of transcription factors MYB-NFIB, or more rarely t(8;9) resulting in MYBL1-NFIB fusion represent robust differential diagnostic marker of adenoid cystic carcinoma. Further it was proved, that the 1p36 deletion can serve as an unfavorable prognostic indicator of adenoid cystic carcinoma, as the patients with 1p36 deletion had significantly lower survival. Second part summarizes new developments about mammary analogue secretory carcinoma (MASC), which was described by our group as a new salivary tumor entity characterized by translocation t(12;15)(p13;q25) resulting in ETV6-NTRK3 fusion. Another novel observation is a discovery of ETV6-RET fusion in a subset of MASC cases. Further, the first two MASCs of nasal mucosa origin have been described. Third part consists...
|
17 |
Germline predisposition to childhood acute lymphoblastic leukemia and bone marrow failure, and mitochondrial DNA variants in leukemiaJärviaho, T. (Tekla) 02 October 2018 (has links)
Abstract
Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children. The overall survival rate has reached to 90%. However, ALL still presents a significant disease burden and is a major cause for deaths in children.
Recently, both inherited germline variants related to ALL susceptibility and somatic genetic variants forming novel subgroups of ALL have been discovered. In this thesis two families with familial ALL were studied. Constitutional heterozygous microdeletion at chromosome 7p12.1p13, including IKZF1, was discovered in the first family with intellectual impairment, overgrowth, and susceptibility to childhood ALL. In the second family, constitutional chromosome translocation was revealed in two individuals with childhood ALL and, subsequently, in seven unaffected family members. The balanced reciprocal translocation t(12;14)(p13.2;q23.1) resulted in breakpoints on two genes; ETV6 on chromosome 12 and RTN1 on chromosome 14. Only a few familial and sporadic ALL cases with germline variants in either IKZF1 or ETV6 have been published, thus supporting the significant role of these constitutional variants in childhood ALL predisposition.
Inherited bone marrow failure syndromes (IBMFS) may predispose to childhood leukemia, including ALL. Two unrelated patients were diagnosed with bone marrow failure without the symptoms of classical IBMFS. Neither patient had any signs of developmental delay or congenital anomalies. Exome sequencing revealed identical c.1457del(p.(Ile486fs)) mutation on the ERCC6L2 gene in both patients. A few patients with IBMFS and ERCC6L2 variants have been described in previous studies. Some of them also had congenital craniofacial anomalies and developmental delay that were not detected in the patients in this thesis.
The ALL cohort study on genetic variation of mitochondrial DNA (mtDNA) included 36 children. Metabolic change where malignant cells uncouple energy production from oxidative phosphorylation (OXPHOS) is one of the established hallmarks of cancer. In the cohort in this study, 22% of patients harbored nonsynonymous variants on mtDNA in the protein-coding genes of OXPHOS enzyme complexes. The somatic non-neutral variants were found in patients with a poor prognosis cytogenetic marker. The results support the hypothesis that cancer cells harbor mtDNA variants that may affect the cell metabolism. / Tiivistelmä
Akuutti lymfoblastileukemia (ALL) on lasten yleisin syöpä. Vaikka nykyisin noin 90 prosenttia paranee, ALL aiheuttaa huomattavan paljon sairastavuutta ja on merkittävä lasten kuolinsyy.
Vastikään on löydetty perinnöllisiä geneettisiä muutoksia, jotka altistavat lapsuusiän ALL:lle. Tutkimuksen kohteena oli kaksi perhettä, joissa vähintään kaksi lasta on sairastunut ALL:aan. Ensimmäisessä perheessä havaittiin lapsuusiän ALL:aan sairastuneilla kehityshäiriöisillä sisaruksilla äidiltä periytyvä heterotsygoottinen deleetio kromosomissa 7p12.1p13, jossa sijaitsee IKZF1-geeni. Toisessa perheessä perinnöllinen kahden kromosomin translokaatio todettiin kahdella lapsuusiän ALL:aan sairastuneella sekä seitsemällä perheenjäsenellä. Balansoitu translokaatio t(12;14)(p13.2;q23.1) aiheuttaa katkaisukohdan ETV6-geeniin kromosomissa 12 ja RTN1-geeniin kromosomissa 14. Tähän mennessä on julkaistu vain muutamia tutkimuksia potilaista, joilla on ollut perinnöllinen muutos joko IKZF1- tai ETV6-geenissä. Näillä geeneillä oletetaan olevan tärkeä merkitys perinnöllisessä alttiudessa sairastua lapsuusiän ALL:aan.
Perinnölliset luuytimen toimintahäiriöt voivat altistaa leukemialle, kuten ALL:lle. Kahdella lapsella todettiin luuytimen toimintahäiriö, mutta ei muita oireita, jotka voisivat liittyä tyypillisiin perinnöllisiin luuytimen toimintahäiriöihin. Eksomisekvensoinnissa todettiin identtinen, homotsygoottinen mutaatio c.1457del(p.(Ile486fs)) ERCC6L2-geenissä. Kirjallisuuslähteiden mukaan vain muutamalla potilaalla on todettu ERCC6L2-geenin muutoksesta johtuva luuytimen toimintahäiriö. Osalla heistä on ollut synnynnäisiä kallon ja kasvojen anomalioita sekä kehityshäiriö, jollaisia tähän tutkimukseen osallistuneilla potilailla ei todettu.
Potilaskohorttitutkimuksessa tutkittiin mitokondriaalisen DNA:n (mtDNA) muutoksia ALL:aan sairastuneilla lapsilla. Syöpäsolut eivät hyödynnä mitokondrion elektroninsiirtoketjua energian tuotantoon, ja tämä aineenvaihdunnan muutos on tunnustettu syövän ominaisuus. Tutkimuksessa havaittiin, että 22 prosentilla potilaista ilmeni diagnoosivaiheessa poikkeavia mtDNA:n muutoksia, jotka olivat elektroninsiirtoketjun entsyymien alayksiköitä koodaavissa geeneissä. Muutoksia todettiin useimmiten potilailla, joilla oli leukemiasoluissa huonon ennusteen geneettinen tekijä. Havaitut muutokset voivat mahdollisesti vaikuttaa leukemiasolun energia-aineenvaihduntaan.
|
18 |
Korelace molekulárně-genetických a morfologických znaků vzácných nádorů slinných žláz / Correlation of Molecular-Genetic and Morphological Markers of Rare Salivary Gland TumorsŠteiner, Petr January 2018 (has links)
Thesis deals with relationship between histomorphological and molecular-genetic findings of selected salivary gland tumors. Author, as a molecular-cytogeneticist mainly focused on detection of tumor-specific translocations of the salivary gland tumors which can serve as differential diagnostic markers. The thesis is composed as a commented files of authors own publications, and it is divided into four parts. First part deepens the knowledge of salivary adenoid cystic carcinoma. It was proved, that t(6;9)(q22-23;p23-24) resulting in fusion of transcription factors MYB-NFIB, or more rarely t(8;9) resulting in MYBL1-NFIB fusion represent robust differential diagnostic marker of adenoid cystic carcinoma. Further it was proved, that the 1p36 deletion can serve as an unfavorable prognostic indicator of adenoid cystic carcinoma, as the patients with 1p36 deletion had significantly lower survival. Second part summarizes new developments about mammary analogue secretory carcinoma (MASC), which was described by our group as a new salivary tumor entity characterized by translocation t(12;15)(p13;q25) resulting in ETV6-NTRK3 fusion. Another novel observation is a discovery of ETV6-RET fusion in a subset of MASC cases. Further, the first two MASCs of nasal mucosa origin have been described. Third part consists...
|
19 |
Nachweis von TEL-Genrekombinationen mittels Southern Blot bei Kindern mit akuter lymphoblastischer LeukämieKothe, Blanka 10 July 2003 (has links)
Das in der vorliegenden Arbeit vorgestellte Verfahren der nicht-radioaktiven Southern Blot Hybridisierung unter Verwendung einer Digoxigenin Markierung hat sich für die Darstellung von Rekombinationen im TEL-Genlokus genomischer DNA als sensitive Vergleichsmethode bewiesen. Es wurden insgesamt 122 Kinder mit dieser Methode auf das Vorliegen der Translokation t(12;21) untersucht. Bei einer nur relevante Faktoren berücksichtigenden Beschränkung des PatientInnenkollektivs auf protokollgerecht nach ALL-REZ BFM behandelte B-Vorläufer-Zell-ALL und Erstrezidive konnte eine Rekombination von TEL in 5 von 65 PatientInnen (7,7%) nachgewiesen werden. Lässt man die Einschlusskriterien der ALL-REZ BFM Studie unberücksichtigt, handelt es sich sogar um 7 von 71 (9,9%) PatientInnen. Damit bestätigen die hier vorliegenden Ergebnisse den Trend der aktuellen Diskussion über die Häufigkeit des Vorliegens des Fusionsgenes TEL-AML1 bei Erstrezidiven, die eine kumulative Inzidenz bei einem 10-jährigen Untersuchungszeitraum von 9 ± 5% angeben. Weiterhin konnte mit ereignisfreien Beobachtungszeiträumen nach dem 1. Rezidiv im Median von 8,6 Jahren ein Trend zu späten Rezidiven und somit eine mittelfristig günstige Prognose für die TEL-Rearrangement positiven Rezidivfälle konstatiert werden. Zusammenfassend kann gesagt werden, dass TEL-AML1 positive PatientInnen eine Subgruppe darstellen, die lange erkrankungsfreie Intervalle mit zur Zeit üblichen Therapieprotokollen erreichen, nach Therapie der Ersterkrankung aber auch nach dem ersten Rezidiv. Auf Grund der sich aus dem retrospektiven PatientInnekollektiv ergebenen Selektion war es nicht möglich, statistisch signifikante Aussagen zur unabhängigen prognostischen Bedeutung für die langfristige Prognose von ALL im Kindesalter mit TEL-Rekombinationen zu treffen. / The presence of TEL/AML1 fusion gene in childhood acute lymphoblastic leukaemia (ALL) defines a subgroup of patients with better than average outcome. Around 20% of the patient at point of initial ALL diagnosis are characterised by this fusion transcript from translocation t(12;21)(p12;q22). However, the prognostic significance of this aberration has recently been disputed by the Berlin-Frankfurt-Munster (BFM) study group due to its relatively high incidence found in relapsed patients (19.6% and 21.9%, in two cohorts). Here we wanted to get more data in a long term follow up retrospect investigation by analysing DNA from frozen conserved bone marrow samples of 65 children. In the study presented here only five out of 65 (7.7%) patients selected as childhood B cell precursor acute lymphoblastic leukaemia only treated according to Berlin-Frankfurt-Munster (BFM) ALL relapse trial protocols (ALL-REZ BFM 82-96) (excluding T-lineage and Philadelphia chromosome (Ph)-positive leukaemia) carry this fusion. The detection was done due to a new developed non-radioactive Southern blotting with a Digoxigenin marked template. We could confirm the still good middle term prognosis in the relapsed TEL-AML1 positive subgroup. The TEL-AML1-positive and negative patients differed with respect to duration of last remission and age at initial diagnosis. At a median follow-up time of 8.6 years, children positive for TEL-AML1 had a higher probability of disease-free survival. Because of the small number of patients in this study it was not possible to get statistical significant facts about the independent prognostic impact for the long term prognosis of ALL in childhood with TEL rearrangement.
|
Page generated in 0.0152 seconds